Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them.

Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to drive growth through innovation, commercial execution, and operational efficiency. The company’s portfolio spans vaccines and treatments for a range of diseases, including its high-profile COVID-19 vaccine, Comirnaty.

A major recent development is the FDA approval of Pfizer Inc. and BioNTech’s updated COVID-19 vaccine, COMIRNATY LP.8.1. Targeting the SARS-CoV-2 sublineage LP.8.1, the vaccine is authorized for adults 65 and older, as well as high-risk individuals aged 5–64. Shipping began immediately to ensure broad access for the upcoming respiratory season, reflecting Pfizer’s commitment to timely public health responses.

Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide

Pixabay/Public Domain

Financially, Pfizer Inc. reported strong second-quarter 2025 results with $14.7 billion in revenue, up 10% year-over-year, driven by key products including Vyndaqel and COVID-19 therapies. The business raised its full-year adjusted earnings outlook to $2.90–$3.10 per share, supported by cost-cutting initiatives expected to save $7.2 billion by 2027, with $4.5 billion anticipated by year-end 2025 through efficiencies in research and manufacturing operations.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.